Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,175 trials

NCT06994845
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Phase 3 · Argentina, Australia, China, Hong Kong, Israel, Japan, Saudi Arabia, United States · 20 sites
Registry update: 9 Sept 2026
NCT07362940
Recruiting
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
Phase 1/2 · China · 5 sites
Registry update: 23 Jan 2026
NCT07281833
Recruiting
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Phase 3 · Belgium, Germany, Portugal · 16 sites
Registry update: 5 Aug 2026
NCT07510321
Recruiting
FL-261 Imaging for Cancer Diagnosis and Staging
Not applicable · China · 1 site
Registry update: 3 Apr 2026
NCT07108270
Recruiting
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Phase 2 · China · 1 site
Registry update: 22 Dec 2025
NCT07730164
Recruiting
One-Page Truth-Telling Aid for Cancer Disclosure
Not applicable · Taiwan · 1 site
Registry update: 28 Jul 2026
NCT07864870
Recruiting
Sarcoma Care Adherence and Survival in Strasbourg
Not applicable · France · 1 site
Registry update: 8 Oct 2026
NCT07330830
Recruiting
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Not applicable · French Guiana, Guadeloupe, Réunion · 3 sites
Registry update: 9 Jan 2026
NCT07279077
Recruiting
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Phase 2 · China · 1 site
Registry update: 26 Dec 2025
NCT07038252
Recruiting
The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients
Not applicable · France · 1 site
Registry update: 14 Sept 2026
2024-520385-57-01
Recruiting
A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
Phase 1 · Bulgaria, Spain, Greece, Romania · 8 sites
Registry update: 30 Jun 2026
NCT07387978
Recruiting
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
Not applicable · Australia · 1 site
Registry update: 4 Feb 2026
NCT07048457
Recruiting
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Phase 2 · United States · 2 sites
Registry update: 7 Oct 2026
NCT07217301
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Phase 3 · China, Japan, United States · 49 sites
Registry update: 2 Nov 2026
NCT07065214
Recruiting
Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy
Not applicable · Germany · 1 site
Registry update: 7 Oct 2026
NCT07227402
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Chile, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Hong Kong, Croatia, Ireland, Italy, South Korea, Mexico, Poland, Singapore, Taiwan, United States · 132 sites
Registry update: 3 Aug 2026
NCT07210086
Recruiting
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
Phase 2 · United States · 1 site
Registry update: 29 Oct 2026
NCT07258745
Recruiting
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
Phase 1 · Poland · 1 site
Registry update: 19 Dec 2025
Conflicting statuses (not updated in the registry for 10 months)
NCT07411963
Recruiting
Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
Not applicable · France · 8 sites
Registry update: 1 Sept 2026
NCT07077447
Recruiting
The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract
Not applicable · Denmark, Norway · 5 sites
Registry update: 22 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.